TNXP (Tonix Pharmaceuticals Holding Corp.)
Insider Trading Activity
Every open-market purchase and sale reported by TNXP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | BRADLEY SAENGER | Chief Financial Officer | J | — | — |
| 2026-06-15 | Carolyn E. Taylor | Director | Buy | — | — |
| 2026-06-09 | Richard Newcomb Stillwell | Director | Buy | — | — |
| 2026-06-09 | SETH LEDERMAN | Chief Executive Officer | Buy | — | — |
| 2026-05-14 | Margaret Smith Bell | Director | A | — | — |
| 2026-05-14 | DAVID L GRANGE | Director | A | — | — |
| 2026-05-14 | James Treco | Director | A | — | — |
| 2026-05-14 | Carolyn E. Taylor | Director | A | — | — |
| 2026-05-14 | James Randolph Jr Hunter | Director | A | — | — |
| 2026-05-14 | RICHARD H BAGGER | Director | A | — | — |
| 2026-05-14 | ADEOYE Y OLUKOTUN | Director | A | — | — |
| 2026-05-14 | Richard Newcomb Stillwell | Director | A | — | — |
| 2026-04-01 | SETH LEDERMAN | Chief Executive Officer | Buy | — | — |
| 2026-03-18 | SETH LEDERMAN | Chief Executive Officer | Buy | — | — |
| 2026-02-26 | BRADLEY SAENGER | Chief Financial Officer | A | — | — |
| 2026-02-26 | JESSICA EDGAR MORRIS | Chief Operating Officer | A | — | — |
| 2026-02-26 | GREGORY M SULLIVAN | Chief Medical Officer | A | — | — |
| 2026-02-26 | SETH LEDERMAN | Chief Executive Officer | A | — | — |
| 2026-02-26 | Siobhan Fogarty | Chief Technology Officer | A | — | — |
| 2025-08-21 | Carolyn E. Taylor | Director | Buy | — | — |
| 2025-08-20 | James Treco | Director | Buy | — | — |
| 2025-06-13 | James Randolph Jr Hunter | Director | A | — | — |
| 2025-05-15 | RICHARD H BAGGER | Director | A | — | — |
| 2025-05-15 | Carolyn E. Taylor | Director | A | — | — |
| 2025-05-15 | Richard Newcomb Stillwell | Director | A | — | — |
| 2025-05-15 | James Treco | Director | A | — | — |
| 2025-05-15 | Margaret Smith Bell | Director | A | — | — |
| 2025-05-15 | ADEOYE Y OLUKOTUN | Director | A | — | — |
| 2025-05-15 | DAVID L GRANGE | Director | A | — | — |
| 2025-05-15 | SETH LEDERMAN | Chief Executive Officer | Buy | — | — |
| 2025-02-28 | James Treco | Director | J | — | — |
| 2025-02-28 | ADEOYE Y OLUKOTUN | Director | J | — | — |
| 2025-02-28 | RICHARD H BAGGER | Director | J | — | — |
| 2025-02-28 | Margaret Smith Bell | Director | J | — | — |
| 2025-02-27 | GREGORY M SULLIVAN | Chief Medical Officer | J | — | — |
| 2025-02-27 | JESSICA EDGAR MORRIS | Chief Operating Officer | J | — | — |
| 2025-02-27 | Siobhan Fogarty | Chief Technology Officer | A | — | — |
| 2025-02-27 | BRADLEY SAENGER | Chief Financial Officer | J | — | — |
| 2025-02-27 | SETH LEDERMAN | Chief Executive Officer | J | — | — |
| 2024-05-24 | Richard Newcomb Stillwell | Director | A | — | — |
| 2024-05-24 | Carolyn E. Taylor | Director | A | — | — |
| 2024-05-24 | Margaret Smith Bell | Director | A | — | — |
| 2024-05-24 | James Treco | Director | A | — | — |
| 2024-05-24 | DAVID L GRANGE | Director | A | — | — |
| 2024-05-24 | RICHARD H BAGGER | Director | A | — | — |
| 2024-05-24 | ADEOYE Y OLUKOTUN | Director | A | — | — |
| 2024-03-06 | SETH LEDERMAN | Chief Executive Officer | A | — | — |
| 2024-02-29 | JESSICA EDGAR MORRIS | Chief Operating Officer | A | — | — |
| 2024-02-29 | GREGORY M SULLIVAN | Chief Medical Officer | A | — | — |
| 2024-02-29 | BRADLEY SAENGER | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 29,006 | — |
| — | Director | 5,000 | — |
| — | Chief Financial Officer | 2,154 | — |
| — | Director | 1,833 | — |
| — | Director | 250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TNXP quote page; the site-wide leaderboard is on the insider transactions hub.